Japan

Multiple myeloma
#Japan #Myeloma #Phase III trial #Regulatory #Sanofi

Sarclisa approved in Japan for newly diagnosed multiple myeloma

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ Phase III study.  Olivier Nataf, Global Head of Oncology at Sanofi,… Read More

#News #Regulatory

Insomnia sufferer
#Insomnia #Japan #Nxera Pharma #Phase III trial

Insomnia treatment approved in Japan

Nxera Pharma Japan has received approval from the Ministry of Health, Labour and Welfare of Japan (MHLW) of its New Drug Application (NDA) for ACT-541468 (daridorexant or Quviviq) in 25 and 50mg doses for the treatment of adult patients with insomnia. The approval of Quviviq, a novel dual orexin receptor… Read More

#News #Regulatory

#Cell therapy #Funding #Japan #Oncology #Shinobi Therapeutics

Shinobi Therapeutics secures $59M grant for iPS-T cell therapy

Shinobi Therapeutics has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The funds will support the development of Shinobi's lead iPS-T cell programme targeting GPC3+ tumours. Shinobi also announced an extension of its Series A round, bringing the… Read More

#Business & Investment #News

Bacteriophage
#Bacteriophage #Graft vs Host Disease #Japan #Phage therapy #Stem cell transplant

Bacteriophage study offers new hope in treating GVHD

Researchers from Japan have identified a bacteriophage-derived enzyme that holds promise for future applications in preventing or treating acute graft-versus-host disease (aGVHD). Acute GVHD is a medical condition that occurs when donor immune cells attack the recipient’s tissues after an allogeneic hematopoietic stem cell transplantation (allo-HCT). Read More

#News

Bacteria in Petri dishes
#Antibiotics #Antimicrobial resistance (AMR) #Drug discovery #Japan #UK

UK-Japan partnership to tackle antimicrobial resistance

Two experts in infectious disease have been selected to be policy fellows as part of a wider Japan-UK collaboration to tackle the growing crisis of antimicrobial resistance (AMR). AMR is a major threat to global health and was responsible for 1.27 million deaths in 2019 alone. Read More

#News

Bowl of rice bran
#Japan #Nanomedicine / nanotechnology #Oncology #Precision medicine #Tokyo University of Science

Rice bran nanoparticles show promise as targeted cancer therapy

Researchers have discovered that nanoparticles derived from rice bran are both effective and safe for the treatment of cancer. Cancer therapies that employ nanoparticles can specifically target cancer cells, sparing healthy tissue. Recent studies have demonstrated that plant-derived nanoparticles (pdNPs) that have therapeutic effects… Read More

#Cancer Research #Editor's Choice #News

Japanese flag
#Astellas Pharma #Gastrointestinal #Japan #Monoclonal antibodies #Oncology

Japan becomes first country to approve Astellas’ gastric cancer mAb

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world. Gastric cancer is the third… Read More

#News #Regulatory

Bladder
#Astellas Pharma #Bladder cancer #Japan #Oncology #Regulatory #Urothelial carcinoma

Japanese regulator reviews first-line bladder cancer combination

Astellas has submitted a supplemental new drug application (sNDA) in Japan for Padcev (enfortumab vedotin (genetical recombination)) with Keytruda (pembrolizumab (genetical recombination)) for the first-line treatment of advanced bladder cancer. If approved, it would be the first combination in Japan to offer an alternative to chemotherapy, the current standard of… Read More

#News #Regulatory

Disabled patient having rehabilitation
#Fujita Health University #Japan #Mitochondria #Muscle atrophy #Muscles

Discovery suggests new treatment for muscle atrophy

Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments. While the disuse of muscles is the most frequent catalyst for muscle atrophy, there are several other possible causes, including chronic diseases, injury and exposure to low-gravity… Read More

#News

Multiple myeloma
#Bristol Myers Squibb #CAR-T #Cell therapy #Immunotherapy #Japan #Myeloma

First CAR-T therapy approved for earlier use in treatment of myeloma

Bristol-Myers Squibb has received manufacturing and marketing approval in Japan for Abecma (idecabtagene vicleucel) as a third-line therapy for relapsed or refractory multiple myeloma (RRMM). Abecma is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy. It is now approved for RRMM patients who have received at… Read More

#News #Regulatory

Akira Hiruma, Hamamatsu Photonics
#Award #Hamamatsu Photonics #Japan #Vrije Universiteit Brussel

Hamamatsu Chairman Akira Hiruma honoured as VUB Fellow

Akira Hiruma, Representative Director and Chairman of the Board of Directors at Hamamatsu Photonics, has been made a VUB Fellow by Vrije Universiteit Brussel (VUB). This recognition was given to recognise Mr Hiruma’s contributions to photonics innovation activities at B-PHOT Brussels Photonics and the global outreach… Read More

#News

Autophagy
#Cancer research #cellular #Japan #Liver cancer #Oncology #Proteomics

Study identifies protein complex with possible role in liver cancer

Scientists in Japan have used a novel technique to identify a protein complex degraded by autophagy that has a possible role in liver cancer. Biomolecular condensates like p62 body have a role in cleansing cellular waste through ‘autophagy’, though much remains unknown about the constituents of… Read More

#Cancer Research #News

Macrophages
#Antibodies #Cancer research #Collaboration #Immuno-oncology #Japan #Macrophages #Oncology #Partnership #UK

Drug discovery partners from UK and Japan target macrophages

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest… Read More

#Cancer Research #News

Laboratory mouse
#Genetics / genomics #Japan #Mouse models #Muscles #Proteins

Study could pave way for new muscle atrophy treatments

Researchers have identified the genetic links between muscle atrophy and two types of myosin, paving the way for a new disease model for scientific research and potential new treatments.  The synergistic action of the muscle proteins myosin and actin enables skeletal muscle movements. The skeletal muscle myosin… Read More

#News

#Gene editing #Genetics / genomics #Japan #Muscular dystrophy #RNA

RNA interference method could treat muscular dystrophy

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy.  Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe… Read More

#Editor's Choice #News

#Biopharmaceuticals #Japan #Pharma Awards

Awards success for Sosei Heptares

Biopharmaceutical company Sosei Group received both Licensing Deal of the Year and Executive of the Year at the first Informa Pharma Intelligence Awards Japan. The Informa Pharma Intelligence Awards Japan recognise outstanding innovations in Japanese pharma and biotech. The categories were judged by a panel of industry experts within academia… Read More

#News